$5 million private placement supports norovirus programme
Antiviral therapeutics company Cocrystal Pharma has announced a $5 million investment from OPKO Health, a longtime investor in the company. The investment will support Cocrystal as it advances its lead norovirus programme towards Phase Ib topline data later this year. Under the terms of the agreement,… Read More